TY - CHAP M1 - Book, Section TI - Drug Elimination and Hepatic Clearance A1 - Sun, He A1 - Zhao, Hong A2 - Shargel, Leon A2 - Yu, Andrew B.C. PY - 2016 T2 - Applied Biopharmaceutics & Pharmacokinetics, 7e AB - Describe the pathways for drug elimination in the body.Compare the clinical implications of hepatic and renal disease on drug therapy.Describe the role of hepatic blood flow, drug protein binding, and intrinsic clearance on hepatic clearance.Explain how the rate of drug elimination may change from first-order elimination to zero-order elimination and the clinical implications of this occurrence.Describe the biotransformation of drugs in the liver and which enzymatic processes are considered “phase I reactions” and “phase II reactions.”List the organs involved in drug elimination and the significance of each.Discuss the relationship between metabolic pathways and enzyme polymorphisms on intrasubject variability and drug–drug interactions.Describe how the exposure of a drug is changed when coadministered with another drug that shares the same metabolic pathway.Define Michaelis–Menton kinetics and capacity-mediated metabolism.Calculate drug and metabolite concentrations for drugs that undergo both hepatic and biliary elimination.Define first-pass metabolism and describe the relationship between first-pass metabolism and oral drug bioavailability.Use urine data to calculate fraction of drug excreted and metabolized.Explain how Michaelis–Menton kinetics can be used to determine the mechanism of enzyme inhibition and transporter inhibition.Describe biliary drug excretion and define enterohepatic drug elimination.Discuss the reasons why bioavailability is variable and can be less than 100%.Describe BDDCS—Biological Drug Disposition Classification System. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/04/23 UR - accesspharmacy.mhmedical.com/content.aspx?aid=1117899442 ER -